SWOG clinical trial number
S0353

Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Local Bladder
Activated
11/15/2006
Closed
10/15/2009
Participants
NCORP, Members, UCOP, Medical Oncologists, Surgeons, Pathologists, Affiliates

Research committees

Genitourinary Cancer

Treatment

Gemcitabine hydrochloride

Eligibility Criteria Expand/Collapse

Pts must have histologically proven, recurrent superficial TCC of the bladder Stage T1 Grade 2-4; Stage Tis; Stage Ta Grade 3-4; or multifocal (>2 lesions) Stage Ta any Grade. Must have rec'd at least 2 previous courses of intravesical BCG up to 3 yrs prior to reg. May have rec'd 1 course of chemo. Must not have rec'd gemcitabine prior to reg. Must have had a TURBT or bladder bx documenting above stage & grade at least 6 wks after last BCG and/or immunotherapy or at least 14 days after previous intravesical chemo and w/in 60 days prior to reg. All visible tumor must have been resected at last bx. Must have available representative slides for central path review. Must have had a negative upper tract imaging study w/in 2 yrs of reg w/no evidence of urethral or renal pelvis TCC. Must not have rec'd any prior pelvic RT nor planning to receive any concurrent RT. Must be offered opportunity to consent for specimen submission per Section 15. Must have Zubrod PS 0-2.

Publication Information Expand/Collapse

2016

Summary and recommendations from the National Cancer Institute's Clinical Trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer

SP Lerner;DF Bajorin;CP Dinney;JA Efstathiou;S Groshen;NM Hahn;D Hansel;D Kwiatkowski;M O'Donnell;J Rosenberg;R Svatek;JS Abrams;H Al-Ahmadie;AB Apolo;J Bellmunt;M Callahan;EK Cha;C Drake;J Jarow;A Kamat;W Kim;M Knowles;B Mann;L Marchionni;D McConkey;L McShane;N Ramirez;A Sharabi;AH Sharpe;D Solit;CM Tangen;AT Amiri;E Van Allen;PJ West;JA Witjes;D Quale Bladder Cancer Apr 27;2(2):165-202

PMid: PMID27376138 | PMC number: PMC4927845

2013

SWOG S0353: Phase II trial of intravesical gemcitabine in patients with non-muscle invasive bladder cancer who recurred following at least two prior courses of bacillus Calmette-Guérin

E Skinner;B Goldman;W Sakr;D Petrylak;H Lenz;CT Lee;S Wilson;M Benson;SP Lerner;CM Tangen;IM Thompson Journal of Urology 190(4):1200-1204;

PMid: PMID23597452 | PMC number: PMC4113593

2012

SWOG S0353: Phase II trial of intravesical gemcitabine in patients with superficial bladder cancer with recurrence following 2 prior courses of BCG

E Skinner;B Goldman;W Sakr;D Petrylak;H Lenz;CT Lee;S Wilson;SP Lerner;C Tangen;IM Thompson Journal of Urology 187, No. 4S, Supplement, e673, #1666; American Urological Association Annual Meeting, oral presentation;

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
SWOG Clinical Trial Number
CTSU/A031901